Approval · Notice of Compliance 30612 · 2023
PANZYGA: Notice of Compliance 30612
Issued May 2, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30612
- Date
- May 2, 2023
- Company
- Octapharma Pharmazeutika Produktionsges M B HVienna, Vienne, Austria
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Manufacturing scale-up
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PANZYGA | Not yet assigned | — |
Medicinal ingredients
- IMMUNOGLOBULIN G (HUMAN) 100 MG per ML